Targeting ion channels for cancer therapy by repurposing the approved drugs

Vijay Pralhad Kale, Shantu Amin, Manoj K. Pandey

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

Ion channels have been shown to be involved in oncogenesis and efforts are being poured in to target the ion channels. There are many clinically approved drugs with ion channels as "off" targets. The question is, can these drugs be repurposed to inhibit ion channels for cancer treatment? Repurposing of drugs will not only save investors' money but also result in safer drugs for cancer patients. Advanced bioinformatics techniques and availability of a plethora of open access data on FDA approved drugs for various indications and omics data of large number of cancer types give a ray of hope to look for possibility of repurposing those drugs for cancer treatment. This article is part of a Special Issue entitled: Membrane channels and transporters in cancers.

Original languageEnglish (US)
Article number81871
Pages (from-to)2747-2755
Number of pages9
JournalBiochimica et Biophysica Acta - Biomembranes
Volume1848
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Drug Repositioning
Ion Channels
Pharmaceutical Preparations
Neoplasms
Oncology
Therapeutics
Membrane Transport Proteins
Computational Biology
Bioinformatics
Carcinogenesis
Availability

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Cell Biology

Cite this

@article{706a5ddd898249078b289bc2aa8fb025,
title = "Targeting ion channels for cancer therapy by repurposing the approved drugs",
abstract = "Ion channels have been shown to be involved in oncogenesis and efforts are being poured in to target the ion channels. There are many clinically approved drugs with ion channels as {"}off{"} targets. The question is, can these drugs be repurposed to inhibit ion channels for cancer treatment? Repurposing of drugs will not only save investors' money but also result in safer drugs for cancer patients. Advanced bioinformatics techniques and availability of a plethora of open access data on FDA approved drugs for various indications and omics data of large number of cancer types give a ray of hope to look for possibility of repurposing those drugs for cancer treatment. This article is part of a Special Issue entitled: Membrane channels and transporters in cancers.",
author = "Kale, {Vijay Pralhad} and Shantu Amin and Pandey, {Manoj K.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1016/j.bbamem.2015.03.034",
language = "English (US)",
volume = "1848",
pages = "2747--2755",
journal = "Biochimica et Biophysica Acta - Biomembranes",
issn = "0005-2736",
publisher = "Elsevier",
number = "10",

}

Targeting ion channels for cancer therapy by repurposing the approved drugs. / Kale, Vijay Pralhad; Amin, Shantu; Pandey, Manoj K.

In: Biochimica et Biophysica Acta - Biomembranes, Vol. 1848, No. 10, 81871, 01.10.2015, p. 2747-2755.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Targeting ion channels for cancer therapy by repurposing the approved drugs

AU - Kale, Vijay Pralhad

AU - Amin, Shantu

AU - Pandey, Manoj K.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Ion channels have been shown to be involved in oncogenesis and efforts are being poured in to target the ion channels. There are many clinically approved drugs with ion channels as "off" targets. The question is, can these drugs be repurposed to inhibit ion channels for cancer treatment? Repurposing of drugs will not only save investors' money but also result in safer drugs for cancer patients. Advanced bioinformatics techniques and availability of a plethora of open access data on FDA approved drugs for various indications and omics data of large number of cancer types give a ray of hope to look for possibility of repurposing those drugs for cancer treatment. This article is part of a Special Issue entitled: Membrane channels and transporters in cancers.

AB - Ion channels have been shown to be involved in oncogenesis and efforts are being poured in to target the ion channels. There are many clinically approved drugs with ion channels as "off" targets. The question is, can these drugs be repurposed to inhibit ion channels for cancer treatment? Repurposing of drugs will not only save investors' money but also result in safer drugs for cancer patients. Advanced bioinformatics techniques and availability of a plethora of open access data on FDA approved drugs for various indications and omics data of large number of cancer types give a ray of hope to look for possibility of repurposing those drugs for cancer treatment. This article is part of a Special Issue entitled: Membrane channels and transporters in cancers.

UR - http://www.scopus.com/inward/record.url?scp=84941260865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941260865&partnerID=8YFLogxK

U2 - 10.1016/j.bbamem.2015.03.034

DO - 10.1016/j.bbamem.2015.03.034

M3 - Review article

C2 - 25843679

AN - SCOPUS:84941260865

VL - 1848

SP - 2747

EP - 2755

JO - Biochimica et Biophysica Acta - Biomembranes

JF - Biochimica et Biophysica Acta - Biomembranes

SN - 0005-2736

IS - 10

M1 - 81871

ER -